Drugs and Devices
This week the National Women’s Health Network was back at the FDA fighting for medically accurate information about the dangers of hormone therapy during menopause.
Bisphosphonate use for prevention has declined in recent years – and that’s a victory! But we’re concerned that a recent article in the Wall Street Journal with the misleading title “More Support for Osteoporosis Drugs: The benefits of bisphosphonates outweigh the risks for many patients” encourages the overuse of drugs that have not proven safe or effective as a preventive measure for women.
The NWHN advocates for the greater participation of women and other key groups in clinical trials for all drugs and devices, and particularly for products that are principally marketed and used by women.
We all know that some pharmaceutical companies put their own corporate profits ahead of patient safety. But, those companies don’t have a lock on this behavior — here’s an example of a medical device company that has also compromised patient safety.